Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug

BeiGene Regains Full Rights to Tislelizumab After Terminating Novartis Deal

Fineline Cube Sep 20, 2023

China-based biotech company BeiGene (NASDAQ: BGNE) has reached a mutual agreement with Novartis (NYSE: NVS)...

Company

Kinnate Biopharma Announces Restructuring and Job Cuts Amid Financial Pressures

Fineline Cube Sep 20, 2023

US-based Kinnate Biopharma Inc., (NASDAQ: KNTE), a company dedicated to the development of small-molecule cancer...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

Fineline Cube Sep 20, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...

Company Drug

Pfizer’s Cibinqo and Everest Medicines’ Cefepime-Taniborbactam Selected for Priority Reviews by CDE

Fineline Cube Sep 20, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that Pfizer’s (NYSE: PFE)...

Company Drug

EMA’s CHMP Supports Gilead’s Veklury for COVID-19 Patients with Hepatic Impairment

Fineline Cube Sep 20, 2023

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Deals

Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors

Fineline Cube Sep 20, 2023

Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...

Policy / Regulatory

NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion

Fineline Cube Sep 20, 2023

The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...

Company Drug

FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension

Fineline Cube Sep 20, 2023

The US Food and Drug Administration (FDA) has granted priority review status to an indication...

Company Deals

Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals

Fineline Cube Sep 20, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...

Company Drug

Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE

Fineline Cube Sep 20, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...

Company Drug

Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens

Fineline Cube Sep 20, 2023

Pfizer (NYSE: PFE) has been granted registration authorization by the European Commission (EC) for Litfulo...

Company Deals

Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings

Fineline Cube Sep 20, 2023

Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of...

Company Drug

Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial

Fineline Cube Sep 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...

Company Drug

Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study

Fineline Cube Sep 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine

Fineline Cube Sep 20, 2023

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...

Company Deals

Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion

Fineline Cube Sep 20, 2023

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with...

Company Deals

Cure Genetics and Frametact Ltd Partner on AAV Vectors for Neurological Diseases

Fineline Cube Sep 19, 2023

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact...

Company Drug

Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial

Fineline Cube Sep 19, 2023

Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its...

Company Deals

BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion

Fineline Cube Sep 19, 2023

Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative...

Company Deals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

Fineline Cube Sep 19, 2023

China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...

Posts pagination

1 … 523 524 525 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.